Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.33 |
| ▸ | CSF1R | P07333 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | YAP1 | P46937 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849669 | 0.90 | DHODH (0.36) | DHODHMAP2K1CSF1RCA1CA2 | |
| SCHEMBL24849394 | 0.85 | DHODH (0.36) | DHODHMAP2K1CSF1RCA1CA2 | |
| SCHEMBL24849417 | 0.84 | KDM4E (0.42) | DHODHMAP2K1CA1CA2CA9 | |
| SCHEMBL30459905 | 0.83 | MAP2K1 (0.35) | DHODHMAP2K1CSF1RCA2CA9 | |
| SCHEMBL23673990 | 0.83 | MAP2K1 (0.35) | DHODHMAP2K1CSF1RCA2CA9 | |
| SCHEMBL24848943 | 0.83 | DHODH (0.34) | DHODHMAP2K1CSF1RCA1CA2 | |
| SCHEMBL24849644 | 0.82 | NUDT1 (0.33) | DHODHMAP2K1CSF1RCA1CA2 | |
| SCHEMBL23673873 | 0.74 | MAP2K1 (0.35) | DHODHMAP2K1CSF1RTGFBR1MAP2K2 | |
| SCHEMBL30866576 | 0.72 | DHODH (0.37) | DHODHMAP2K1MAP2K2 | |
| SCHEMBL24195914 | 0.71 | LMNA (0.38) | CA1CA2CA9LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | DHODH 2249/4885MAP2K1 17/4885CSF1R 1365/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | DHODH 3092/4885MAP2K1 162/4885CSF1R 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.